Biocon Biologics and Viatris’s Semglee preferred on Express Scripts’ largest formulary in US Read more
Biocon Biologics insulin manufacturing facility in Malaysia completes USFDA (PAI) inspection Read more
Inter-changeable designation for Semglee in the US is a milestone achievement for Biocon Biologics Read more
Approval of first interchangeable biosimilar insulin to increase competition with payer contracts: GlobalData Read more
Biocon Biologics and Viatris receive US FDA approval for maiden interchangeable biosimilar Semglee Read more